Neurodegenerative tauopathies, including Alzheimer’s disease (AD), are characterized by the intraneuronal accumulation and pathological neuron-to-neuron spread of hyperphosphorylated aggregated tau protein, along with elevated extracellular levels of soluble hyperphosphorylated tau, measurable in the cerebrospinal fluid (CSF) and plasma (1). This evidence concerns the gene MAPT and Alzheimer disease.